Latest filing published 09 Jun 2026 for Iovance Biotherapeutics, INC..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Finckenstein Friedrich Graf in Iovance Biotherapeutics, Inc., where the filings describe the role as senior executive. The record holds 48 filings, for trades running from 14 June 2022 to 5 June 2026.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The latest filing, published on 9 June 2026, reports an option exercise in Iovance Biotherapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
23 of 23 declarations